血小板生成素水平预测罗米司亭治疗化疗所致血小板减少症的疗效
结果显示,达到中度或优效反应者的基线TPO水平显著低于未达到者,TPO水平与基线血小板计数及反应比例呈负相关,与最低有效罗米司亭剂量呈正相关。ROC分析确定中度反应TPO阈值≤457 pg/mL,优效反应≤260 pg/mL。
要点
- 基线TPO水平较低者接受罗米司亭治疗更可能获得中度或优效血小板反应。
- TPO水平与基线血小板计数及反应比例负相关,与最低有效罗米司亭剂量正相关。
- ROC分析提示TPO≤457 pg/mL预测中度反应,≤260 pg/mL预测优效反应。
核心结论
- TPO水平可预测CIT患者对罗米司亭的治疗反应,较低水平预示更高的反应概率和反应深度。
研究设计与样本
- 中位年龄62岁,女性占41.3%,中位罗米司亭治疗持续时间14周(IQR 4-38周)。
主要发现
- TPO水平与基线血小板计数及反应比例呈负相关,与最低有效罗米司亭剂量呈正相关。
关键数值与推荐
- 临床反应定义为血小板≥75×10^9/L且较治疗前基线升高≥30×10^9/L。
- 中度反应定义为>0且≥0.6的血小板评估次数满足临床反应标准,优效反应为≥0.8。
- ROC分析(Youden指数)确定中度反应TPO阈值≤457 pg/mL,优效反应≤260 pg/mL。
临床怎么用
- 对CIT患者使用罗米司亭前可检测基线TPO水平,低水平者可能更受益且所需剂量更低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chemotherapy-induced thrombocytopenia (CIT) is a common complication of cancer treatment. Evidence has emerged supporting use of romiplostim to treat CIT but predicting clinical response to romiplostim is not possible. To determine utility of endogenous thrombopoietin (TPO) as a biomarker of romiplostim response, we performed an observational cohort study of patients with CIT and known baseline TPO levels receiving romiplostim. For weekly on-romiplostim platelet (Plt) count assessment, clinical response was defined as Plt ≥ 75 × 109 /L and ≥ 30 × 109 /L above pretreatment baseline. Overall, moderate, and superior classes of treatment response were defined based on fraction of Plt assessments meeting clinical response criteria (> 0, ≥ 0.6, and ≥ 0.8, respectively). Sixty-three patients with CIT were included; median age was 62 years, 41.3% were female, and median (IQR) romiplostim treatment duration was 14 (4-38) weeks. Median (IQR) TPO was lower in patients achieving moderate response to romiplostim vs those who did not, 234 (135-1085) pg/mL vs 665 (244-1970) pg/mL (p = .034) and lower still in patients achieving superior response vs those who did not, 212 (91-690) pg/mL versus 559 (173-1851) pg/mL (p = .023). Negative correlations were found between TPO level and baseline Plt and TPO level and response fraction. A positive correlation was found between TPO level and lowest effective romiplostim dose. In receiver operating characteristic (ROC) analysis, optimally discriminant TPO level thresholds (as defined by Youden's Index) were ≤ 457 pg/mL for moderate response and ≤ 260 pg/mL for superior response. In conclusion, TPO levels predict response to romiplostim in CIT, with lower levels predicting improved probability and depth of response.
引用
- Song AB, Goodarzi K, Karp Leaf R, et al. Thrombopoietin level predicts response to treatment with romiplostim in chemotherapy-induced thrombocytopenia. Am J Hematol. 2021. PMID: 34453757. doi:10.1002/ajh.26338
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。